<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Levack AE</submitter><funding>National Institute of Arthritis and Musculoskeletal and Skin Diseases</funding><funding>Orthopaedic Research and Education Foundation</funding><funding>NIAMS NIH HHS</funding><pagination>1143-1153</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8716667</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>40(5)</volume><pubmed_abstract>There has been increasing interest in the use of a synthetic absorbable calcium sulfate (CaSO&lt;sub>4&lt;/sub> ) for local antibiotic delivery in orthopaedic infections. The purpose of this study was to quantify elution kinetics of six antibiotics (amikacin, meropenem, fosfomycin, minocycline, cefazolin, and dalbavancin) from a clinically relevant CaSO&lt;sub>4&lt;/sub> bead model and compare elution and antimicrobial activity to the current clinical gold standards: vancomycin and tobramycin. Antibiotic-loaded synthetic CaSO&lt;sub>4&lt;/sub> beads were immersed in phosphate buffered saline and incubated at 37°C. Eluent was harvested at eight time points over 28 days. Antibiotic concentrations were measured by high performance liquid chromatography to quantify elution rates. CaSO&lt;sub>4&lt;/sub> beads demonstrated burst release kinetics. Dalbavancin, cefazolin, and minocycline all demonstrated similar elution profiles to vancomycin. Amikacin and meropenem demonstrated favorable elution profiles and durations of above-minimum inhibitory concentration when compared to tobramycin. Clinical Significance: This study provides important novel data regarding the utility of amikacin, meropenem and dalbavancin as alternative choices to place in CaSO&lt;sub>4&lt;/sub> carriers when treating orthopaedic infections.</pubmed_abstract><journal>Journal of orthopaedic research : official publication of the Orthopaedic Research Society</journal><pubmed_title>Identifying alternative antibiotics that elute from calcium sulfate beads for treatment of orthopedic infections.</pubmed_title><pmcid>PMC8716667</pmcid><funding_grant_id>T32 AR007281</funding_grant_id><funding_grant_id>18‐070</funding_grant_id><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Carli AV</pubmed_authors><pubmed_authors>Miller AO</pubmed_authors><pubmed_authors>Turajane K</pubmed_authors><pubmed_authors>Levack AE</pubmed_authors><pubmed_authors>Driscoll DA</pubmed_authors><pubmed_authors>Bostrom MP</pubmed_authors><pubmed_authors>Wellman DS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identifying alternative antibiotics that elute from calcium sulfate beads for treatment of orthopedic infections.</name><description>There has been increasing interest in the use of a synthetic absorbable calcium sulfate (CaSO&lt;sub>4&lt;/sub> ) for local antibiotic delivery in orthopaedic infections. The purpose of this study was to quantify elution kinetics of six antibiotics (amikacin, meropenem, fosfomycin, minocycline, cefazolin, and dalbavancin) from a clinically relevant CaSO&lt;sub>4&lt;/sub> bead model and compare elution and antimicrobial activity to the current clinical gold standards: vancomycin and tobramycin. Antibiotic-loaded synthetic CaSO&lt;sub>4&lt;/sub> beads were immersed in phosphate buffered saline and incubated at 37°C. Eluent was harvested at eight time points over 28 days. Antibiotic concentrations were measured by high performance liquid chromatography to quantify elution rates. CaSO&lt;sub>4&lt;/sub> beads demonstrated burst release kinetics. Dalbavancin, cefazolin, and minocycline all demonstrated similar elution profiles to vancomycin. Amikacin and meropenem demonstrated favorable elution profiles and durations of above-minimum inhibitory concentration when compared to tobramycin. Clinical Significance: This study provides important novel data regarding the utility of amikacin, meropenem and dalbavancin as alternative choices to place in CaSO&lt;sub>4&lt;/sub> carriers when treating orthopaedic infections.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2024-11-20T01:22:08.596Z</modification><creation>2024-11-20T01:22:08.596Z</creation></dates><accession>S-EPMC8716667</accession><cross_references><pubmed>34191350</pubmed><doi>10.1002/jor.25135</doi></cross_references></HashMap>